Exclusive-J&J CEO pay irks investors upset with opioid lawsuits fallout By Reuters
By Jessica DiNapoli (Reuters) - Johnson & Johnson (NYSE:JNJ) is coming under fire from some investors who are raising questions about companies that give their chief executives hefty pay raises despite facing billions of dollars in legal costs over their role in the U.S. opioid crisis. J&J has always excluded certain one-time costs such as litigation expenses from its calculation of stock...
Continue reading